Search results
Results from the WOW.Com Content Network
You can often tell the health of the stock market by the number and performance of initial public offerings, or IPOs. As 2022 has seen a bear market in the major averages, it's not surprising at ...
Follow @leokornsun In 2013, 33 biotech companies went public, raising a total of $2.5 billion from their IPOs and easily eclipsing the previous record of 26 biotech companies that raised $1.9 ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
For premium support please call: 800-290-4726 more ways to reach us
The Morningstar Rating for Funds is a rating system for investment funds operated by Morningstar. The Star Rating, debuted in 1985, a year after Morningstar was founded. The 1- to 5-star system, "looks at a fund's risk-adjusted return based on its performance over three, five and 10 years and on its volatility. The highest rating of five stars ...